Benign prostatic hyperplasia
Conditions
Interventions
Experimental group:Xialiqi Capsule + Tamsulosin
Sponsors
Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
Male
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with BPH who have symptoms of frequent urination and dysuria, diagnosed by digital rectal examination, B-ultrasound, and uroflowmetry; 2. IPSS>=13 and/or QOL>=3 points; 3. Prostate volume > 25ml; 4. The maximum urine flow rate is less than 15ml/s; 5. Residual urine volume 50 years; 7. The patients voluntarily participated and signed the informed consent; 8. PSA4ng/ml; 9. In line with the dialectical standard of TCM spleen-kidney qi deficiency and phlegm stasis syndrome.
Exclusion criteria
Exclusion criteria: 1. With other diseases that cause urination disorders, such as prostate cancer; 2. The patient or his authorizer is unwilling to comply with the study protocol; 3. Upper urinary tract hydrops, bladder stones, repeated hematuria, urinary tract infections caused by benign prostatic hyperplasia; 4. Patients with benign prostatic hyperplasia who have failed invasive treatment and who have a history of pelvic surgery or injury; 5. Patients with severe diabetes, hypertension, cardiovascular and cerebrovascular diseases; 6. Patients with major organ dysfunction, such as liver and kidney insufficiency; 7. Psychopaths; 8. Those with allergies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostatic hyperplasia I-PSS score;Score of deficiency in spleen and kidney and phlegm stasis syndrome;Maximum urinary flow rate;Average urinary flow rate;Quality of life score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prostate volume;Residual urine volume;Chronic prostatitis symptom score; | — |
Countries
China
Contacts
Public ContactLiu Liwei
Second Hospital of Tianjin Medical University
Outcome results
None listed